Get the Stockscreener App
14.49
1.29%
-0.19
Edgewise Therapeutics Inc stock is traded at $14.49, with a volume of 698.48K.
It is down -1.29% in the last 24 hours and down -1.96% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$14.68
Open:
$14.44
24h Volume:
698.48K
Relative Volume:
0.42
Market Cap:
$1.63B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-9.3677
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
-6.21%
1M Performance:
-1.96%
6M Performance:
-51.97%
1Y Performance:
-16.58%
1-Day Range:
$14.39
$14.94
1-Week Range:
$14.39
$16.30
52-Week Range:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.49 | 1.63B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 3.8%What's Next? - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $39.78 Average PT from Analysts - MarketBeat
Enliven to sell $200M in stock after positive drug trial - BizWest
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Transcript : Edgewise Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03 - marketscreener.com
Bank of America Corp DE Has $1.31 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Ameriprise Financial Inc. Purchases Shares of 22,584 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Royal Bank of Canada Reaffirms Outperform Rating for Edgewise Therapeutics (NASDAQ:EWTX) - Defense World
Bank of America Corp DE Decreases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics (EWTX) Receives Reaffirmed 'Outperform' Ra - GuruFocus
RBC Capital maintains outperform rating on Edgewise Therapeutics stock By Investing.com - Investing.com India
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Invests $2.40 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference - Eastern Progress
Muscle Disease Leader Edgewise Therapeutics Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Two Sigma Investments LP Has $3.52 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
Certain Common Stock of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
(EWTX) Technical Data - news.stocktradersdaily.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Nuveen Asset Management LLC - MarketBeat
Polar Asset Management Partners Inc. Has $1.72 Million Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX) - Seeking Alpha
Nuveen Asset Management LLC Acquires 158,452 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Woodline Partners LP Has $15.15 Million Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring a 174% Potential Upside in Biotech - DirectorsTalk Interviews
BNP Paribas Financial Markets Makes New $883,000 Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
106,562 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Purchased by Point72 Asset Management L.P. - MarketBeat
Frazier Life Sciences Management L.P. Cuts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics’ SWOT analysis: promising rare disease pipeline faces challenges By Investing.com - Investing.com South Africa
Edgewise Therapeutics’ SWOT analysis: promising rare disease pipeline faces challenges - Investing.com India
Polar Asset Management Partners Inc. Trims Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Tang Capital Management LLC Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Deutsche Bank AG Grows Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
How to Take Advantage of moves in (EWTX) - news.stocktradersdaily.com
Soleus Capital Management L.P. Acquires New Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Northern Trust Corp Acquires 35,426 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):